论文部分内容阅读
动脉粥样硬化是有免疫系统参与的慢性炎症反应性疾病,CD11/CD18在其炎性反应中发挥重要作用。CD11/CD18缺失或阻断可通过减少白细胞粘附、脂纹形成,干预经皮冠状动脉腔内成形术术后狭窄、再狭窄过程等多个环节影响动脉粥样硬化的形成过程。这些研究深化了对动脉粥样硬化分子机制的认识,以CD18为新靶点的药物,可能会给临床动脉粥样硬化性疾病的预防、诊断和治疗带来新的突破。
Atherosclerosis is a chronic inflammatory disease involving the immune system. CD11 / CD18 plays an important role in its inflammatory response. The deletion or block of CD11 / CD18 can affect the formation of atherosclerosis by reducing leukocyte adhesion, formation of lipid streaks, interventional stenosis after percutaneous transluminal coronary angioplasty, and restenosis. These studies have deepened our understanding of the molecular mechanism of atherosclerosis. The drug targeting CD18 as a new target may bring new breakthroughs in the prevention, diagnosis and treatment of clinical atherosclerotic diseases.